Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 29 Neoplasms 8 Neoplasm Metastasis 8 Brain Neoplasms 5 Prostatic Neoplasms 4 Ovarian Neoplasms 4 Glioma 4 Endometrial Neoplasms 4 Triple Negative Breast Neoplasms 3 Neoplasms by Site 3 Breast Diseases 3 Squamous Cell Carcinoma of Head and Neck 2 Recurrence 2 Meningioma 2 Head and Neck Neoplasms 2 Glioblastoma 2 Uterine Cervical Neoplasms 1 Unilateral Breast Neoplasms 1 Spinal Cord Neoplasms 1 Small Cell Lung Carcinoma 1 Sarcoma, Kaposi 1 Sarcoma, Ewing 1 Sarcoma 1 Recurrent Ovarian High Grade Serous Adenocarcinoma 1 Pathologic Complete Response 1 Pancreatic Neoplasms 1 Neurofibromatosis 1 1 Neoplasms, Squamous Cell 1 Neoplasm, Residual 1 Multiple Myeloma 1

Interventions

Letrozole 4 Fulvestrant 3 toripalimab 2 elacestrant 2 Anastrozole 2 trastuzumab deruxtecan 1 ribociclib 1 palbociclib 1 exemestane 1 disitamab vedotin 1 abemaciclib 1 Selective Estrogen Receptor Modulators 1 RAD1901 1 Paclitaxel 1 Lead 1 Injections 1 Goserelin 1 Gonadotropin-Releasing Hormone 1 Everolimus 1 Alpelisib 1 AZD9833 1 AZD5305 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Advanced Breast Cancer × abemaciclib × 90 days × Clear all

NCT06380751 2026-05-15

EvoPAR-BR01

AstraZeneca

Phase 3 Recruiting

Advanced Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡